Petrice M. Cogswell, Heather J. Wiste, Stephen D. Weigand, Terry M. Therneau, Michael E. Griswold, Joel B. Braunstein, Tim West, Philip B. Verghese, Jonathan Graff-Radford, Alicia Algeciras-Schimnich, Val J. Lowe, Christopher G. Schwarz, Matthew L. Senjem, Jeffrey L. Gunter, David S. Knopman, Prashanthi Vemuri, Ronald C. Petersen, Clifford R. Jack Jr.
{"title":"Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET","authors":"Petrice M. Cogswell, Heather J. Wiste, Stephen D. Weigand, Terry M. Therneau, Michael E. Griswold, Joel B. Braunstein, Tim West, Philip B. Verghese, Jonathan Graff-Radford, Alicia Algeciras-Schimnich, Val J. Lowe, Christopher G. Schwarz, Matthew L. Senjem, Jeffrey L. Gunter, David S. Knopman, Prashanthi Vemuri, Ronald C. Petersen, Clifford R. Jack Jr.","doi":"10.1002/alz.14629","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Limited data exist on the utility of plasma biomarkers to predict incident abnormal amyloid positron emission tomography (PET). In this study we evaluate the association of plasma Alzheimer's disease (AD) biomarkers with amyloid PET progression among initially amyloid PET negative (A−) individuals.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We included 290 A−, cognitively unimpaired Mayo Clinic Study of Aging participants. We estimated the association of each baseline plasma biomarker with progression from A− to A+ and with rate of amyloid PET change.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Interquartile range differences in amyloid beta 42/40, percent phosphorylated tau 217 (%p-tau217), and Amyloid Probability Score 2 were associated with 1.29 (<i>P</i> = 0.09), 1.38 (<i>P</i> < 0.001), and 1.20 (<i>P</i> = 0.05) increases, respectively, in the hazard of progression from A− to A+ and 0.27 (<i>P</i> = 0.16), 0.50 (<i>P</i> = 0.007), and 0.28 (<i>P</i> = 0.15) Centiloid/year increases, respectively, in annual rate of amyloid PET change.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Plasma %p-tau217 may be a useful screening tool to enrich for participants with increased likelihood of progressing from normal to abnormal amyloid PET in a primary prevention trial.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Plasma phosphorylated tau 217 was associated with amyloid positron emission tomography progression, negative to positive.</li>\n \n <li>The associations were weaker for amyloid beta 42/40 and Amyloid Probability Score 2.</li>\n \n <li>Age and apolipoprotein E ε4 carriership were also important predictors.</li>\n \n <li>These markers may be useful for enrichment of a primary prevention trial.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14629","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14629","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Limited data exist on the utility of plasma biomarkers to predict incident abnormal amyloid positron emission tomography (PET). In this study we evaluate the association of plasma Alzheimer's disease (AD) biomarkers with amyloid PET progression among initially amyloid PET negative (A−) individuals.
METHODS
We included 290 A−, cognitively unimpaired Mayo Clinic Study of Aging participants. We estimated the association of each baseline plasma biomarker with progression from A− to A+ and with rate of amyloid PET change.
RESULTS
Interquartile range differences in amyloid beta 42/40, percent phosphorylated tau 217 (%p-tau217), and Amyloid Probability Score 2 were associated with 1.29 (P = 0.09), 1.38 (P < 0.001), and 1.20 (P = 0.05) increases, respectively, in the hazard of progression from A− to A+ and 0.27 (P = 0.16), 0.50 (P = 0.007), and 0.28 (P = 0.15) Centiloid/year increases, respectively, in annual rate of amyloid PET change.
DISCUSSION
Plasma %p-tau217 may be a useful screening tool to enrich for participants with increased likelihood of progressing from normal to abnormal amyloid PET in a primary prevention trial.
Highlights
Plasma phosphorylated tau 217 was associated with amyloid positron emission tomography progression, negative to positive.
The associations were weaker for amyloid beta 42/40 and Amyloid Probability Score 2.
Age and apolipoprotein E ε4 carriership were also important predictors.
These markers may be useful for enrichment of a primary prevention trial.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
